These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 31750596)

  • 1. Rates of clinically significant prostate cancer in African Americans increased significantly following the 2012 US Preventative Services Task Force recommendation against prostate specific antigen screening: A Single Institution Retrospective Study.
    Arace J; Flores V; Monaghan T; Robins D; Karanikolas N; Winer A; Weiss J
    Int J Clin Pract; 2020 Feb; 74(2):e13447. PubMed ID: 31750596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abrogation of survival disparity between Black and White individuals after the USPSTF's 2012 prostate-specific antigen-based prostate cancer screening recommendation.
    Kim IE; Jang TL; Kim S; Modi PK; Singer EA; Elsamra SE; Kim IY
    Cancer; 2020 Dec; 126(23):5114-5123. PubMed ID: 32888321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do African-American men need separate prostate cancer screening guidelines?
    Shenoy D; Packianathan S; Chen AM; Vijayakumar S
    BMC Urol; 2016 May; 16(1):19. PubMed ID: 27165293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. African-American men with prostate cancer have larger tumor volume than Caucasian men despite no difference in serum prostate specific antigen.
    Fuletra JG; Kamenko A; Ramsey F; Eun DD; Reese AC
    Can J Urol; 2018 Feb; 25(1):9193-9198. PubMed ID: 29524974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of African American race on prostate cancer detection on repeat prostate biopsy in a veteran population.
    Sterling WA; Weiner J; Schreiber D; Mehta K; Weiss JP
    Int Urol Nephrol; 2016 Dec; 48(12):2015-2021. PubMed ID: 27580731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of the 2012 United States Preventive Services Task Force statement on prostate-specific antigen screening: analysis of urologic and primary care practices.
    Perez TY; Danzig MR; Ghandour RA; Badani KK; Benson MC; McKiernan JM
    Urology; 2015 Jan; 85(1):85-9. PubMed ID: 25440819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do racial disparities exist in the use of prostate cancer screening and detection tools in veterans?
    Hudson MA; Luo S; Chrusciel T; Yan Y; Grubb RL; Carson K; Scherrer JF
    Urol Oncol; 2014 Jan; 32(1):34.e9-18. PubMed ID: 23506962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of the U.S. Preventive Services Task Force recommendations against prostate specific antigen screening on prostate biopsy and cancer detection rates.
    Bhindi B; Mamdani M; Kulkarni GS; Finelli A; Hamilton RJ; Trachtenberg J; Zlotta AR; Evans A; van der Kwast TH; Toi A; Fleshner NE
    J Urol; 2015 May; 193(5):1519-24. PubMed ID: 25481037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in the aggressiveness of prostate cancer among Korean, Caucasian, and African American men: A retrospective cohort study of radical prostatectomy.
    Jeong IG; Dajani D; Verghese M; Hwang J; Cho YM; Hong JH; Kim CS; Ahn H; Ro JY
    Urol Oncol; 2016 Jan; 34(1):3.e9-14. PubMed ID: 26345648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate cancer screening and detection in inner-city and underserved men.
    Anai S; Pendleton J; Wludyka P; Williams C; Nelms L; Pettaway C; Rosser CJ
    J Natl Med Assoc; 2006 Apr; 98(4):515-9. PubMed ID: 16623063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
    Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
    BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening.
    Kearns JT; Holt SK; Wright JL; Lin DW; Lange PH; Gore JL
    Cancer; 2018 Jul; 124(13):2733-2739. PubMed ID: 29781117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.
    ; Grossman DC; Curry SJ; Owens DK; Bibbins-Domingo K; Caughey AB; Davidson KW; Doubeni CA; Ebell M; Epling JW; Kemper AR; Krist AH; Kubik M; Landefeld CS; Mangione CM; Silverstein M; Simon MA; Siu AL; Tseng CW
    JAMA; 2018 May; 319(18):1901-1913. PubMed ID: 29801017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations.
    Jemal A; Fedewa SA; Ma J; Siegel R; Lin CC; Brawley O; Ward EM
    JAMA; 2015 Nov; 314(19):2054-61. PubMed ID: 26575061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Prostate-specific Antigen (PSA) Screening Trials and Revised PSA Screening Guidelines on Rates of Prostate Biopsy and Postbiopsy Complications.
    Gershman B; Van Houten HK; Herrin J; Moreira DM; Kim SP; Shah ND; Karnes RJ
    Eur Urol; 2017 Jan; 71(1):55-65. PubMed ID: 26995328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the United States Preventive Services Task Force 'D' recommendation on prostate cancer screening and staging.
    Eapen RS; Herlemann A; Washington SL; Cooperberg MR
    Curr Opin Urol; 2017 May; 27(3):205-209. PubMed ID: 28221220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes observed in prostate biopsy practices in an inner city hospital with a high risk patient population following the 2012 uspstf psa screening recommendations.
    Tam AW; Khusid J; Inoyatov I; Becerra AZ; Davila J; Chouhan JD; Weiss JP; Hyacinthe LM; McNeil BK; Winer AG
    Int Braz J Urol; 2018; 44(4):697-703. PubMed ID: 29617073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of the USPSTF Grade D Recommendation Against Prostate-Specific Antigen Screening With Prostate Cancer-Specific Mortality.
    Burgess L; Aldrighetti CM; Ghosh A; Niemierko A; Chino F; Huynh MJ; Efstathiou JA; Kamran SC
    JAMA Netw Open; 2022 May; 5(5):e2211869. PubMed ID: 35576008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate Needle Biopsy Outcomes in the Era of the U.S. Preventive Services Task Force Recommendation against Prostate Specific Antigen Based Screening.
    Banerji JS; Wolff EM; Massman JD; Odem-Davis K; Porter CR; Corman JM
    J Urol; 2016 Jan; 195(1):66-73. PubMed ID: 26254722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recruitment strategies and comparison of prostate cancer-specific clinical data on African-American and Caucasian males with and without family history.
    Mandal DM; Sartor O; Halton SL; Mercante DE; Bailey-Wilson JE; Rayford W
    Prostate Cancer Prostatic Dis; 2008; 11(3):274-9. PubMed ID: 18268528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.